Dec 01, 2016

Farmak joins the ISPOR Community

In November 2016, Farmak joined the International Society for Pharmacoeconomics and Outcomes Research — ISPOR. ISPOR promotes implementation of pharmacoeconomic study results into the global health care practice (research evaluating the health care impact, including clinical and economic studies).

 The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a non-profit public organization established to exchange educational and scientific data. ISPOR promotes implementation of pharmacoeconomic study results into the global health care practice (research evaluating the health care impact, including clinical and economic studies).

 In total, the Society unites more than 9,500 members from various institutions, universities and companies around the world. Farmak has become one of 29 member companies of ISPOR, along with Johnson & Johnson, Merck and Lilly.

Oleg Syarkevych, Farmak Business Development Director: “After the Resolution of On Reimbursement of Medicinal Products was brought into force by the Government of Ukraine in 2017, issues of pharmacoeconomics became the key ones when considering inclusion of a product into the company’s portfolio and, accordingly, the list of compensation. Bearing this in mind, we draw on experience of the European Union, the United States on converting results of pharmacoeconomic studies into reasoned decisions in the health care. ISPOR membership allows Farmak to participate in international scientific congresses, educational courses, and training sessions. Farmak gains access to reports and research papers on pharmacoeconomics published by the organization, and  also the Company gains the opportunity to publish its own research results and present them to the scientific community.”

Farmak took part in the 19th Annual European Congress in Vienna in November. Oleg Romanovych Syarkevych, Business Development Director of Farmak, participated in the Congress and presented a poster presentation "Reimbursement of insulin for diabetes: prospects for implementation in the healthcare of Ukraine".

Back to the News